Preferred Stock Offerings
By Preferred Stock Channel Staff, updated Wed, April 24, 3:35 AM
This Slide: #494 of 620 |
Slide #494. Cell Therapeutics, Inc. — Preferred Stock Offering
Company:
Cell Therapeutics, Inc. (CTIC)
Date announced:
9/12/2013
Shares Offered:
15,000
Preferred Stock Offering Details:
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that it has agreed to sell 15,000 shares of its Series 18 Preferred Stock directly to Quogue Capital LLC and an affiliate of Perceptive Advisors LLC in a registered direct offering conducted without an underwriter or placement agent for gross proceeds of approximately $15 million (the "Offering"). The net proceeds from the Offering, after deducting estimated offering expenses, will be approximately $14.8 million.
CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers where there is an unmet medical need. Co. has one commercially approved product, VONJO (pacritinib), which has received approval in the U.S. by the U.S. Food and Drug Administration for the treatment of adult patients with intermediate or primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10^9/L.
Open the CTIC Page at Preferred Stock Channel »
|
Open the CTIC Page at Preferred Stock Channel (in a new window) »
Free CTIC Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Hold (2.50 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|